Core Viewpoint - China Tongru (01763) has seen its stock price increase by over 130% this year, with a recent rise of 7.94% to HKD 24.48, driven by significant developments in the nuclear medicine sector [1] Group 1: Company Developments - On November 5, Novartis announced that its radioligand therapy (RLT) drug Pluvicto received approval from the National Medical Products Administration for two indications, which is expected to boost the domestic nuclear medicine industry [1] - China Tongru has launched carbon isotope products, marking a breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials [1] - The company has officially initiated the construction of the second phase of its stable isotope base project, positioning itself as a leader in the complete industrial chain of breath test products [1] Group 2: Industry Insights - The approval of Pluvicto is anticipated to further ignite interest in the domestic nuclear medicine sector, with diagnostic nuclear drugs expected to see increased demand alongside therapeutic drugs [1] - Analysts suggest focusing on companies like China Tongru that are leading in the development of new isotopes and new targets within the nuclear medicine space [1]

消息面上，11月5日，诺华宣布其放射配体疗法(RLT)药物Pluvicto的两个适应症同时获得国家药监局批 准。据悉，Pluvicto为诺华旗下的一款核药爆品。平安证券指出，Pluvicto的获批有望进一步点燃国内核 医学行业热度，AD诊断核药有望随着治疗药物一同放量，建议关注国内在新核素和新靶点方面布局领 先的企业，比如中国同辐等。 值得注意的是，10月31日，中国同辐发布碳同位素产品，标志我国在稳定同位素领域高端技术突破"卡 脖子"难题，中国成为全球少数具备高丰度13CO气体和碳13尿素原料药生产能力的国家，公司成为完整 掌握呼气试验产品全产业链的龙头企业。同日，公司正式启动稳定同位素基地二期项目建设。 中国同辐(01763)再涨超8%，年内股价累涨逾130%。截至发稿，涨7.94%，报24.48港元，成交额1302.97 万港元。 ...

Core Viewpoint - China Tongru (01763) has made a significant breakthrough in the field of stable isotopes by launching carbon isotope products, marking China's advancement in high-end technology and reducing reliance on imports for key medical materials [1] Group 1: Product Launch and Significance - The launch of high-abundance 13CO gas and carbon-13 urea raw materials positions China as one of the few countries capable of producing these essential components for medical applications [1] - The new products will eliminate China's complete dependence on imports for 13CO used in urea breath tests for detecting Helicobacter pylori infections, enhancing domestic production capabilities [1] Group 2: Industry Impact and Future Projects - The announcement coincides with the initiation of the second phase of the stable isotope base project, which will ensure a stable supply of high-abundance 13CO gas and other raw materials for gastrointestinal disease treatments [1] - This development is expected to significantly contribute to national health improvement and the high-quality development of medical isotopes, aligning with the "Healthy China" initiative [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 1 當日，中國同輻正式啟動穩定同位素基地二期項目建設，項目建成後，中國同輻 將形成高豐度13CO氣體、碳13尿素原料藥以及其它覆蓋胃腸道疾病治療藥物原 料藥的穩定供應能力，對提升國民健康水平、促進醫用同位素高質量發展、服務 「健康中國」建設具有重要意義。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月31日 自願性公告 中國同輻突破呼氣診斷關鍵原料技術 成為完整掌握呼氣試驗產品全產業鏈的龍頭企業 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會（「董事會」）欣然宣佈，10月31日，中國同輻發佈碳同位素產品，標 誌着我國在穩定同位素領 ...